Clearstead Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Clearstead Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$875	Buy	+3	New	+$993	﹤0.01%	2690

Other funds holding PRAX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Clearstead Advisors's PRAX Position: Q3 2026 in Review

Clearstead Advisors opened a new position in Praxis Precision Medicines (PRAX) in Q3 2026: 3 shares worth $875. The stake represents ﹤0.01% of the portfolio and ranks #2690 among its holdings.

113 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

Clearstead Advisors held 3 shares of Praxis Precision Medicines worth $875 as of Q3 2026.
Praxis Precision Medicines was a new Clearstead Advisors position in Q3 2026.
Praxis Precision Medicines made up ﹤0.01% of Clearstead Advisors's portfolio in Q3 2026, its #2690 holding.
113 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Clearstead Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.